Petra Magri Gatt, David Pisani, Simon Mifsud, Michael J Boffa
{"title":"Paediatrics and genetics.","authors":"Petra Magri Gatt, David Pisani, Simon Mifsud, Michael J Boffa","doi":"10.1093/ced/llaf240","DOIUrl":"10.1093/ced/llaf240","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1895-1897"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David G Caetano, Mariana Pedroso, Duarte Flor, Joana Xará, José Carlos Cardoso, Maria Manuel Brites
{"title":"Persistent cribriform facial lesions as presentation of superficial granulomatous pyoderma.","authors":"David G Caetano, Mariana Pedroso, Duarte Flor, Joana Xará, José Carlos Cardoso, Maria Manuel Brites","doi":"10.1093/ced/llaf232","DOIUrl":"10.1093/ced/llaf232","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1923-1925"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"At the mercy of my condition: a patient perspective on living with Gorlin syndrome.","authors":"Aoife Boyle, Benvon Moran","doi":"10.1093/ced/llaf245","DOIUrl":"10.1093/ced/llaf245","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1888-1889"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan
{"title":"Prescribing practices among psoriasis experts for patients with concomitant malignancy: a survey of International Psoriasis Council members.","authors":"Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan","doi":"10.1093/ced/llaf198","DOIUrl":"10.1093/ced/llaf198","url":null,"abstract":"<p><strong>Background: </strong>The management of moderate-to-severe psoriasis in patients with concurrent or previous malignancy presents a unique clinical challenge. Despite the transformative impact of biologic therapies on psoriasis treatment, the exclusion of patients with malignancy from clinical trials has led to a paucity of data regarding the safety and efficacy of systemic and biologic agents in this subgroup. Clinicians are thus often compelled to rely on registry data, real-world evidence and expert opinion when navigating these complex cases.</p><p><strong>Objectives: </strong>To investigate prescribing practices among psoriasis experts for systemic and biologic therapies in patients with severe psoriasis and concomitant malignancy. The study aimed to elucidate trends in decision making, perceptions of treatment risks and adherence to multidisciplinary approaches.</p><p><strong>Methods: </strong>An electronic survey was disseminated to 141 members of the International Psoriasis Council (IPC) between December 2023 and June 2024. The self-administered questionnaire examined respondents' demographics, guideline familiarity and preferences for systemic and biologic therapies across five malignancy types (breast cancer, melanoma, prostate cancer, lymphoma and metastatic renal cell carcinoma) at varying remission intervals. Data were analysed descriptively.</p><p><strong>Results: </strong>Fifty-seven IPC councillors completed the survey (40%). Anti-interleukin-17 agents were the most commonly selected therapies across all malignancy scenarios for patients in remission, reflecting growing confidence in their safety profiles. For active malignancies, apremilast was the most frequently chosen agent, particularly for breast cancer (61%), melanoma (56%) and metastatic renal cell carcinoma (49%). Tumour necrosis factor-α inhibitors and fumaric acid esters were the least frequently selected treatments for active malignancies. The majority of respondents (70%) believed current guidelines lacked clarity on treating psoriasis in the context of malignancy. Nearly half (49%) reported always consulting oncology teams before initiating systemic therapy for patients with recent malignancy diagnoses, underscoring the importance of a multidisciplinary approach.</p><p><strong>Conclusions: </strong>This study highlights significant variability in prescribing practices and a strong preference for biologics such as anti-IL-17 agents and apremilast. The findings underscore the urgent need for malignancy-specific guidelines informed by robust long-term safety data to support optimal decision making and improve patient outcomes.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1818-1826"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on 'Efficacy and safety of vismodegib in basosquamous carcinoma: insights from a retrospective study including 18 patients': basosquamous carcinoma at the crossroads: histological ambiguity, treatment potential and the path to clinical consensus.","authors":"Aparna Potluru, Daryl Teo, Pick Ngor-Woo","doi":"10.1093/ced/llaf195","DOIUrl":"10.1093/ced/llaf195","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1867-1868"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hannah R Chang, Emily Murphy, Duaa Abdel Hameid, Madeline Ngo, Melissa M Mauskar
{"title":"A modified tissue-saving technique with silver nitrate to obliterate tunnels for hidradenitis suppurativa.","authors":"Hannah R Chang, Emily Murphy, Duaa Abdel Hameid, Madeline Ngo, Melissa M Mauskar","doi":"10.1093/ced/llaf216","DOIUrl":"10.1093/ced/llaf216","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1926-1928"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Austin J Piontkowski, Celina Dubin, Sach Thakker, Jeremy Orloff, Camille M Powers, Caroline Silver, Benjamin Ungar, Nicholas Gulati
{"title":"Vitiligo and associated comorbidities: a case-control study in the All of Us database.","authors":"Austin J Piontkowski, Celina Dubin, Sach Thakker, Jeremy Orloff, Camille M Powers, Caroline Silver, Benjamin Ungar, Nicholas Gulati","doi":"10.1093/ced/llaf228","DOIUrl":"10.1093/ced/llaf228","url":null,"abstract":"<p><p>Recent research has established an association between vitiligo and other autoimmune diseases. Given the systemic inflammation, there are likely other comorbidities with vitiligo that are not as well established. We identified 1074 patients with vitiligo and 4296 matched controls in the US All of Us database. Conditional logistic regression estimated the odds ratios (OR) and 95% confidence intervals (CI) of 29 selected comorbid conditions for patients with vitiligo compared with matched controls. The Benjamini-Hochberg method was used to adjust P-values. In logistic regression, patients with vitiligo had significantly increased likelihoods of atherosclerotic disease (OR 1.78, 95% CI 1.48-2.14, P < 0.001), hypertension (OR 1.75, 95% CI 1.50-2.03, P < 0.001) and hyperlipidaemia (OR 2.32, 95% CI 1.99-2.72, P < 0.001). Patients with vitiligo additionally carried a significant bone and joint, autoimmune, endocrine and psychiatric comorbidity burden. This convergence highlights the multifaceted nature of vitiligo, prompting a need to investigate therapeutic approaches capable of addressing both vitiligo and its varied comorbidities.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1856-1859"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mental health and psychosocial outcomes in survivors of severe cutaneous adverse reactions: a scoping review.","authors":"Suyeon Hong, Joyce Quon, Caroline A Nelson","doi":"10.1093/ced/llaf202","DOIUrl":"10.1093/ced/llaf202","url":null,"abstract":"<p><p>Severe cutaneous adverse reactions (SCARs) are rare drug-induced eruptions, most notably Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Their psychological impact is increasingly recognized, with UK guidelines for SJS-TEN recommending psychological evaluation, and a continuing medical education review for DRESS recommending monitoring for anxiety, depression and post-traumatic stress disorder (PTSD) for 1 year. However, monitoring for adverse psychosocial outcomes has not been standardized. This scoping review aims to characterize the existing literature on psychosocial outcomes in survivors of SCARs and highlight gaps in knowledge. Following the Joanna Briggs Institute guidelines, we searched MEDLINE, Embase and PsycInfo for primary literature using terms related to SCARs and psychosocial outcomes. After screening 865 records, 24 studies were included. Of these studies, 88% investigated SJS-TEN and 21% addressed DRESS. In total, 44-54% and 21-44% of survivors of SJS-TEN and 36-63% and 50% of survivors of DRESS screened positive for anxiety and depression, respectively, on the Hospital Anxiety and Depression Scale. Overall, 17-51% of survivors of SJS-TEN and 50% of survivors of DRESS had scores indicating PTSD using variations of the Impact of Events Scale. Quality of life, fear of medications and altered relationships with medical providers were also frequently identified. The heterogeneity in outcome measures underscores the need for a specific, standardized tool to assess for psychosocial complications in survivors of SCARs. This review highlights needs for improved psychosocial support in survivors of SJS-TEN and DRESS, as well as research into psychosocial outcomes in unexplored SCARs such as acute generalized exanthematous pustulosis and generalized bullous fixed drug eruption.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1755-1765"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}